Follow
Dr Manzoor Ahmad Mir
Title
Cited by
Cited by
Year
Tumor microenvironment promotes breast cancer chemoresistance
U Mehraj, AH Dar, NA Wani, MA Mir
Cancer chemotherapy and pharmacology, 1-12, 2021
1552021
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities
MAMNAW Umar Mehraj, Rais A. Ganai, Muzafar A. Macha, Abid Hamid, Mohammed A ...
cellular Oncology 44 (5), 1-18, 2021
782021
Targeting different pathways using novel combination therapy in triple negative breast cancer
MA Mir, H Qayoom, U Mehraj, S Nisar, B Bhat, NA Wani
Current Cancer Drug Targets 20 (8), 586-602, 2020
732020
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
H Qayoom, NA Wani, B Alshehri, MA Mir
Future Oncology 17 (31), 4185-4206, 2021
682021
Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
S Sofi, U Mehraj, H Qayoom, S Aisha, A Almilaibary, M Alkhanani, MA Mir
Medical Oncology 39 (9), 133, 2022
642022
Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives
U Mehraj, H Qayoom, MA Mir
Breast Cancer 28 (3), 539-555, 2021
612021
Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications
S Sofi, U Mehraj, H Qayoom, S Aisha, SMB Asdaq, A Almilaibary, MA Mir
Medical Oncology 39 (6), 106, 2022
592022
Nanobodies: The “magic bullets” in therapeutics, drug delivery and diagnostics
MA Mir, U Mehraj, BA Sheikh, SS Hamdani
Human antibodies 28 (1), 29-51, 2020
562020
Introduction to costimulation and costimulatory molecules. Developing Costimulatory Molecules for Immunotherapy of Diseases
M Mir
Academic Press, 2015
552015
Introduction to Costimulation and Costimulatory Molecules.
MA Mir
Developing Costimulatory Molecules for Immunotherapy of Diseases 3, 147-198, 2015
502015
Double-crosser of the immune system: macrophages in tumor progression and metastasis
MA Mir, U Mehraj
Current Immunology Reviews 15 (2), 172-184, 2019
442019
Development of new therapeutics to meet the current challenge of drug resistant tuberculosis
BA Sheikh, BA Bhat, U Mehraj, W Mir, S Hamadani, MA Mir
Current pharmaceutical biotechnology 22 (4), 480-500, 2021
412021
Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications
U Mehraj, U Mushtaq, MA Mir, A Saleem, MA Macha, MN Lone, A Hamid, ...
Seminars in Cancer Biology 86, 769-783, 2022
402022
Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: a comprehensive analysis
U Mehraj, S Aisha, S Sofi, MA Mir
Advances in Cancer Biology-Metastasis 4, 100037, 2022
402022
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
Manzoor MA, Haseeb A, Qadri H
Current Drug Targets 22 (12), 1424-1436, 2021
352021
Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi
H Qadri, AH Shah, SM Ahmad, B Alshehri, A Almilaibary, MA Mir
Saudi Journal of Biological Sciences 29 (9), 103376, 2022
332022
Signaling through CD80: an approach for treating lymphomas
MA Mir, JN Agrewala
Expert opinion on therapeutic targets 12 (8), 969-979, 2008
312008
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis
H Qayoom, S Sofi, MA Mir
Immunologic Research 71 (4), 588-599, 2023
302023
Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study
H Qayoom, U Mehraj, S Sofi, S Aisha, A Almilaibary, M Alkhanani, MA Mir
Medical Oncology 39 (10), 158, 2022
302022
Expression pattern and prognostic significance of chemokines in breast cancer: an integrated bioinformatics analysis
U Mehraj, B Alshehri, AA Khan, AA Bhat, P Bagga, NA Wani, MA Mir
Clinical Breast Cancer 22 (6), 567-578, 2022
292022
The system can't perform the operation now. Try again later.
Articles 1–20